AstraZeneca: ENHERTU Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
July 28, 2023
July 28, 2023
WILMINGTON, Delaware, July 28 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release:
* * *
Data support ongoing discussions with global health authorities
* * *
High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously . . .
* * *
Data support ongoing discussions with global health authorities
* * *
High-level results from the primary analysis of the ongoing DESTINY-PanTumor02 Phase II trial showed ENHERTU(R) (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful progression-free survival (PFS) and overall survival (OS) in previously . . .